Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M115Revenue (TTM) $M1.8Net Margin (%)-2,413.6Altman Z-Score1.6
Enterprise Value $M34.8EPS (TTM) $-1.8Operating Margin %-2,334.1Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-2,413.6Higher ROA y-yY
Price/Book1.410-y EBITDA Growth Rate %--Quick Ratio16.2Cash flow > EarningsY
Price/Sales61.15-y EBITDA Growth Rate %--Current Ratio16.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-40.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-50.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.8ROIC % (ttm)-99,504.8Gross Margin Increase y-yN

Gurus Latest Trades with OCUL

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

OCUL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OCUL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-06-09Buy10,000$6.7-30.75view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-11-17Buy10,000$8.25-43.76view
Fortune JamesCOO 2015-09-15Sell9,470$17.16-72.96view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-09-14Buy15,000$16.5-71.88view
Versant Venture Capital III, L10% Owner 2015-06-15Sell320,000$22-78.91view
Warden Charles MDirector, 10% Owner 2015-06-15Sell320,000$22-78.91view
SVLSF IV, LLC10% Owner 2015-06-10Sell1,119,000$22-78.91view
Versant Venture Capital III, L10% Owner 2015-06-10Sell427,000$22-78.91view
Warden Charles MDirector, 10% Owner 2015-06-10Sell427,000$22-78.91view
Polaris Venture Management Co.10% Owner 2015-02-02Sell500,000$29.5-84.27view

Quarterly/Annual Reports about OCUL:

    News about OCUL:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

    More From Other Websites
    [$$] Ocular Shares Fall After FDA Rejects Eye Pain Drug Jul 25 2016
    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ocular Therapeutix,... Jul 25 2016
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocular... Jul 25 2016
    Ocular Therapeutix Gets Complete Response Letter From FDA For Its NDA For DEXTENZA Jul 25 2016
    Ocular stock drops 7% after eye pain drug fails to get FDA approval Jul 25 2016
    FDA rejects Ocular's post-operative eye pain treatment Jul 25 2016
    FDA rejects Ocular Therapeutix post-operative eye pain treatment Jul 25 2016
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 25 2016
    Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the... Jul 25 2016
    8:06 am Ocular Therapeutix receives CRL from the FDA regarding its NDA for DEXTENZA 0.4 mg, for... Jul 25 2016
    Ocular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the... Jul 25 2016
    Ocular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference Jul 06 2016
    Ocular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference Jul 06 2016
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jun 23 2016
    7 Biopharma Companies That Destroyed Shareholders Last Week Jun 12 2016
    This stock’s crash is a cautionary tale on the dangers of betting on biotech IPOs Jun 07 2016
    Why Ocular Therapeutix (OCUL) Stock Is Tanking Today Jun 06 2016
    Why Adamis Pharmaceuticals, Immunomedics and Three Other Stocks Are Deep in Red Today? Jun 06 2016
    The 5 Biggest Biotech and Pharma Losers From ASCO Jun 06 2016
    Stocks to Watch: Adamis Pharmaceuticals, Ocular Therapeutix, ProNAi Therapeutics Jun 06 2016
    Why Ocular Therapeutix Is Sinking Despite Mixed Results Jun 06 2016
    Ocular Therapeutix Inc Conference Call to Discuss the Results of Phase 3 Clinical Trial for... Jun 06 2016
    Stock Futures Inch Higher as Wall Street Awaits Yellen Jun 06 2016
    Ocular Therapeutix's late-stage trial of pink eye treatments fails to meet objective Jun 06 2016
    Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences Jun 02 2016
    Ocular Therapeutix™ Reports First Quarter 2016 Financial Results and Provides Corporate Update May 10 2016
    Ocular Therapeutix reports 1Q loss May 10 2016
    Ocular Therapeutix™ to Report First Quarter 2016 Financial Results May 03 2016
    Ocular TherapeutixTM Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release... Apr 27 2016
    Ocular TherapeutixTM to Host Investor Day on April 6, 2016 Mar 28 2016
    Ocular Therapeutix reports 4Q loss Mar 10 2016
    Ocular TherapeutixTM Strengthens Executive Management Team with the Appointment of Highly Regarded... Jan 11 2016
    Ocular Therapeutix, Inc. (Nasdaq: OCUL) to Ring The Nasdaq Stock Market Opening Bell Dec 14 2015
    Ocular Therapeutix™ Announces Encouraging Top-Line Results from Exploratory Phase 2 Trial for... Dec 14 2015
    Ocular Therapeutix, Inc. (Nasdaq: OCUL) to Ring the Nasdaq Stock Market Opening Bell Dec 11 2015
    Ocular Therapeutix™ Announces FDA Acceptance of NDA Filing for DEXTENZA™ for the Treatment of... Dec 09 2015
    Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference Nov 24 2015
    Ocular Therapeutix™ Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA™ for the... Nov 24 2015
    Ocular Therapeutix reports 3Q loss Nov 10 2015
    Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results Nov 10 2015
    Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James... Nov 09 2015
    Ocular Therapeutix™ to Report Third Quarter 2015 Financial Results Nov 03 2015
    Ocular Therapeutix™ to Participate in Three Conferences in November 2015 Oct 28 2015
    Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal... Sep 14 2015
    Ocular Therapeutix™ to Participate in Two Investor Conferences in September 2015 Sep 03 2015
    Ocular Therapeutix reports 2Q loss Aug 10 2015
    Ocular Therapeutix reports 1Q loss May 15 2015
    Ocular Therapeutix slumps on eye treatment study Apr 06 2015
    Ocular Therapeutix reports 4Q loss Mar 10 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)